Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40

A method of treating an immune disease by antagonizing CD40 activity in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of antibody polypeptide comprising a first variable domain comprising three complementarity determining regions (CDR), wherein

• (a) CDR1 region comprises the amino acid sequence of the CDR1 region of BMS3h-56-269 (amino acids 31 to 35 of SEQ ID NO:
• 417),
• (b) CDR2 region comprises the amino acid sequence of the CDR2 region of BMS3h-56-269 (amino acids 50 to 66 of SEQ ID NO:
• 417), and
• (c) CDR3 region comprises the amino acid sequence of the CDR3 region of BMS3h-56-269 (amino acids 99 to 105 of SEQ ID NO:
• 417),
• or
• the amino acid sequences of the CDR1, CDR2, and CDR3 regions are selected from amino acids 31 to 35, 50 to 66, and 99-105, respectively, of one of the antibody polypeptide sequences selected from the group consisting of:
• SEQ ID NO:
• 317;
• SEQ ID NO:
• 318;
• SEQ ID NO:
• 320;
• SEQ ID NO:
• 321;
• SEQ ID NO:
• 324;
• SEQ ID NO:
• 325;
• SEQ ID NO:
• 326;
• SEQ ID NO:
• 327;
• SEQ ID NO:
• 331;
• SEQ ID NO:
• 332;
• SEQ ID NO:
• 333;
• SEQ ID NO:
• 334;
• SEQ ID NO:
• 335;
• SEQ ID NO:
• 336;
• SEQ ID NO:
• 337;
• SEQ ID NO:
• 341;
• SEQ ID NO:
• 342;
• SEQ ID NO:
• 343;
• SEQ ID NO:
• 344;
• SEQ ID NO:
• 345;
• SEQ ID NO:
• 346;
• SEQ ID NO:
• 347;
• SEQ ID NO:
• 348;
• SEQ ID NO:
• 349;
• SEQ ID NO:
• 350;
• SEQ ID NO:
• 353;
• SEQ ID NO:
• 355;
• SEQ ID NO:
• 356;
• SEQ ID NO:
• 358;
• SEQ ID NO:
• 366;
• SEQ ID NO:
• 367;
• SEQ ID NO:
• 376;
• SEQ ID NO:
• 379;
• SEQ ID NO:
• 381;
• SEQ ID NO:
• 386;
• SEQ ID NO:
• 394;
• SEQ ID NO:
• 403;
• SEQ ID NO:
• 405;
• SEQ ID NO:
• 412;
• and SEQ ID NO:
• 419,
• wherein the antibody polypeptide binds CD40.